Case reports: efalizumab-associated lymphoproliferative disease.
Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.
Division of Neoplastic Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA. sbommaka@mcw.edu
Satya
S
Bommakanti
Amol
A
Patil
Camellia
C
Eshoa
Christopher R
CR
Chitambar
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D004854:Herpesvirus 4, Human / Q000254:growth & development; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000139:chemically induced / Q000175:diagnosis* / Q000821:virology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced / Q000175:diagnosis* / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000139:chemically induced / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C472181:efalizumab